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Abstract 
Objective: Despite recent development of HTA-methods, there are still methodological gaps for the 
assessment of complex health technologies. The INTEGRATE-HTA guidance for effectiveness, 
economic, ethical, socio-cultural, and legal aspects, deals with challenges when assessing complex 
technologies, such as heterogeneous study designs, multiple stakeholder perspectives, and 
unpredictable outcomes. The objective of this article is to outline this guidance and describe the 
added value of integrating these assessment aspects. 
Methods: Different methods were used to develop the various part of the guidance, but all draw on 
existing, published knowledge, and were supported by stakeholder involvement. The guidance was 
modified after application in a case study and in response to feedback from internal and external 
reviewers. 
Results: The guidance consists of five parts, addressing five core aspects of HTA, all presenting 
stepwise approaches based on the assessment of complexity, context, and stakeholder involvement. 
The guidance on effectiveness, health economics and ethics aspects focus on helping users choose 
appropriate, or further develop, existing methods. The recommendations are based on existing 
ŵĞƚŚŽĚƐ ?applicability for dealing with problems arising with complex interventions. The guidance 
offers new frameworks to identify socio-cultural and legal issues, along with overviews of relevant 
methods and sources. 
Conclusion: The INTEGRATE-HTA guidance outlines a wide range of methods and facilitates 
appropriate choices among them. The guidance enables understanding of how complexity matters 
for HTA and brings together assessments from disciplines, such as epidemiology, economics, ethics, 
law, and social theory. This indicates relevance for a broad range of technologies. 
Keywords: technology assessment biomedical, technology assessment (health), methods, complex 
health interventions 
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Introduction 
Although there is no univocal agreement on what defines a complex health intervention, most 
definitions share some common features. Aspect of complex interventions often highlighted includes 
flexibility, non-standardisation (the form depend on the context), multiple interacting components, 
and non-linear causal pathways (1). Health Technology Assessment (HTA) of complex health 
interventions, such as disease management programmes, lifestyle interventions, and digital health 
interventions, may be challenging due to e.g. heterogeneous study designs and outcome reporting 
(1-3). The EU-funded project INTEGRATE-HTA offers guidance addressing specific challenges of 
complexity in a series of methodological documents (4-8) integrated within the overarching 
INTEGRATE-HTA Model (9). This paper presents key messages from the Guidance for assessing 
effectiveness, economic aspects, ethical aspects, socio-cultural aspects and legal aspects in complex 
technologies (4). The INTEGRATE-HTA Model (9) enables a coordinated assessment of these 
assessment aspects along with contextand implementation issues (6) and patient characteristics (5). 
A logic model (7) provides a structured overview of the factors and aspects surrounding the 
technology and visualizes the assessment results. The understanding of integrated HTA that 
underpins INTEGRATE-HTA does not only include considering multiple assessment aspects 
individually, but also how these aspects are related, and how these interrelationships affect the 
assessment process and outcome. 
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INTEGRATE-HTA identifies five key aspects of complexity relevant to HTA; multiple and changing 
perspectives, indeterminate phenomena, uncertain causality, unpredictable outcomes and 
historicity, time and path dependency/ethical complexity (10). These characteristics can be 
illustrated by the example of home based palliative care, where the interaction between the many 
different stakeholders entail multiple and changing perspectives, the range of models and different 
target populations means that the technology cannot be strictly defined, the individualized care and 
flexibility of services entail uncertain causal pathways between intervention and outcome, and the 
outcomes themselves may be unexpected due to many uncertainties involved (11). As all 
technologies are to a certain degree complex, the guidance recommends to make a systematic 
consideration of whether complexity is relevant for a given assessment, and provides structured help 
for doing so. 
The guidance builds on previous efforts, including the HTA Core Model (12) and the Health 
Technology Assessment Handbook (13). Thus, it serves to complement and expand upon existing HTA 
guidance. The guidance is based on an understanding that all five aspects must be addressed when 
complex technologies are to be assessed including ethical, socio-cultural and legal aspects, which still 
tend to be ignored in current HTA practice. This comprehensiveness is crucial as a complex health 
technology mutually interacts with the societal context. This calls for sensitivity towards ethical, 
socio-cultural, and legal norms, in order to understand the impact and acceptance of the technology. 
The objective of this article is to give an outline of this Guidance and its elements, as well as to 
indicate the added value of applying it in HTA, in an integrated manner. 
 
Methods 
The guidance comprises five assessment dimensions in HTA; effectiveness, economics, ethics, socio-
cultural, and legal aspects. According to the nature of the respective fields the methods by which the 
guidance was developed, and its focus, differs across the five dimensions. For example, legal research 
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and practice has developed from a different paradigm than assessment of clinical intervention 
effectiveness. However, one common feature is that the specific guidance parts draw on existing and 
published knowledge in the fields of HTA, complexity science, as well as knowledge of research 
methodologies in the five respective fields. Another common feature is that all guidance parts were 
informed by stakeholder involvement, including health care professionals, patients and relatives 
from six European countries in the scoping process, as well as internal and external HTA researchers. 
The concepts and methods suggested in the different guidance parts have been applied in a case 
study on reinforced home based palliative care (11), and subsequently adapted through 
collaboration and feedback between the researchers in the project. The INTEGRATE-HTA working 
group consist of HTA-researchers, and experts in all relevant aspects of HTA, from five European 
countries. Finally, the guidance was revised after valuable feedback from internal and external 
reviewers. Throughout the process of guidance development, there have been extensive 
collaborations aiming at harmonization and integration across various parts of the guidance. 
 
Results 
An overview of each of the assessment aspects of the INTEGRATE-HTA guidance (4) is presented in 
the following, i.e. what content and tools the user will find when applying the guidance, and the 
expected benefits thereof. Complexity exists along a spectrum as there is no clear-cut distinction 
between simple and complex technologies. This makes the systematic approaches to describe 
aspects of complexity presented in this guidance important in order to understand when the 
complexity matters for HTA and for decision makers. This is relevant for all assessment aspects and 
for most health technologies. 
 
Guidance for the assessment of effectiveness 
An assessment of effectiveness comprises a variety of steps, from forming the question, to designing 
and conducting searches, identifying evidence, appraising the quality of and synthesizing evidence, as 
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well as effectively communicating the results. Comprehensive resources outlining this process exist 
(12, 14), thus for this guidance we focus on two aspects of the effectiveness assessment process 
which may prove especially problematic for complex interventions. Specifically, the effectiveness 
guidance offers a flexible guide to help users choose appropriate methods for dealing with 
heterogeneous study designs and for synthesizing effectiveness evidence. It is based on the 
assumption that there is no one-size-fits-all solution for dealing with heterogeneous study designs 
and synthesizing evidence. As such, for any assessment, multiple options may be suitable and 
appropriate, including a range of quantitative, qualitative and mixed-methods approaches. 
Nevertheless, case-specific aspects can make certain methods more suitable and appropriate than 
others. In this part of the guidance, we considered these case-specific aspects to be the specific 
research question; the specific technology under assessment and the system in which it exists; the 
resulting complexity; and the available evidence. This guidance describes these issues in detail and 
discusses their potential implications for the choice of method.  
The application of this guidance involves working through a series of steps. The first three steps occur 
a priori before beginning the assessment, and include 1) conducting a comprehensive scope of the 
effectiveness assessment; 2) gaining a thorough understanding of the characteristics of available 
methods; 3) (conditionally) specifying methods a priori. For some technologies, these steps may be 
sufficient for choosing appropriate methods for dealing with heterogeneous study designs and 
synthesizing evidence. For others, however, it may still be unclear whether these methods are 
appropriate, and thus the a priori decision should be treated as conditional.  
Once the assessment commences and the potentially relevant studies have been identified, the final 
two steps may be necessary, including 4) assessing methodological and clinical heterogeneity in the 
identified evidence base; and 5) specifying final decision on methods. 
In working through these steps the user must consider issues such as the type of question being 
ĂƐŬĞĚ ?Ğ ?Ő ? “/ƐƚŚĞƚĞĐŚŶŽůŽŐǇĞĨĨĞĐƚŝǀĞ ? ?ĂƐĐŽŵƉĂƌĞĚƚŽ “tŚĂƚƉĂƌƚƐŽĨƚŚĞŝŶƚĞƌǀĞŶƚŝŽŶĂƌĞŵŽƐƚ
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ĞĨĨĞĐƚŝǀĞ ? ? ? ?ĂƐǁĞůůĂƐƚŚĞƐƉĞĐŝĨŝĐĚĞĨŝŶŝƚŝŽŶƐĨŽƌƚŚĞƉŽƉƵůĂƚŝŽŶ ?ƚĞĐŚŶŽůŽŐǇ ?ĐŽŵƉĂƌŝƐŽŶĂŶĚ
outcomes to be included. This may sound straightforward, but in the presence of complexity the 
hammering down of these issues may become substantially more difficult, as the boundaries around 
the technology begin to blur, as the number of outcomes and stakeholders increases, and as context 
and implementation become more important. Regarding dealing with a heterogeneous evidence 
base, the guidance provides information to help the user to consider and balance directness of 
evidence with the risk of bias, so that the best-available and most informative evidence can be 
utilized, whilst the risk of bias within the evidence base is explicit, understood and dealt with 
appropriately. The inclusion of only randomized controlled trials, for example, will ensure that the 
risk of bias of included studies remains relatively low, compared to the inclusion of other non-
randomized study designs such as interrupted time-series or controlled before-after studies. In some 
cases, however, these non-randomized study designs can provide much more direct evidence than 
highly controlled randomized controlled trials, and may thus be considered more informative. This 
guidance document describes a range of quantitative meta-analytical and summary methods for 
synthesizing evidence of effectiveness, and discusses implications for the various facets of 
complexity. The following simple examples should help the reader understand how certain facets of 
complexity may match well to specific evidence synthesis methods: 1) If the assessed technology is 
not a single technology, but rather several variations of a technology, network meta-analysis may 
allow the assessment to compare variations of the technology that have not been compared directly 
in the primary literature. 2) If varying contextual aspects are likely to influence effectiveness, meta-
regression could be useful for assessing the effect of such aspects. 3) If included studies are simply 
too heterogeneous with regard to the population, technology, outcomes, or study methods to justify 
statistical pooling, a graphical summary approach like the forest plot without a summary statistic or 
the harvest plot can summarize study effects in a clear, concise manner. 
Additionally, the guidance briefly introduces how stakeholder input, as well as qualitative methods 
and mixed-methods may also play an important role. One limitation of this guidance is that it does 
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not provide concrete guidance for assessing the risk of bias from heterogeneous types of evidence. 
Currently, there is no widely accepted standard for assessing risk of bias across study designs. Much 
work, however, is happening in this field, and some resources do exist for assessing risk of bias across 
study designs (15, 16). 
Each effectiveness assessment is at least somewhat unique, meaning there is a limit to how specific 
such guidance can be. In the effectiveness guidance, however, a range of options for study design 
inclusion and evidence synthesis are documented and described, and it is emphasized that the user 
makes decisions regarding these methods only after substantial consideration of the research 
question, the technology and the system in which it exists, the resulting complexity and the existing 
evidence. The guidance also suggests that controlled flexibility in deciding upon methods may be 
necessary and beneficial to ensure that effectiveness assessments provide the best possible evidence 
for informing decisions.  
 
Guidance for the assessment of economic aspects 
Complex interventions and particularly those that interact with context and setting throw up special 
problems for health economic assessment (17). We developed guidance that focuses on the use of a 
systems approach for undertaking model based economic evaluation of complex interventions in a 
complex setting (4). The guidance on practice is based on a combination of problem structuring 
methods and quantitative modelling. Whilst conceptual frameworks exist for structuring the 
consideration of public health interventions (18) no similar conceptual frameworks exist for more 
generic complex interventions. 
A systems approach to economic evaluation is recommended to provide a useful conceptual 
framework for addressing a number of the issues raised by complexity. It takes as its starting point 
^ƚĞƉ ? ? ‘ĞĨŝŶŝƚŝŽŶŽĨƚŚĞ,dŽďũĞĐƚŝǀĞĂŶĚƚĞĐŚŶŽůŽŐǇ ?ĂŶĚ^ƚĞƉ ? ‘ƌĞĂƚŝŽŶŽĨĂŶŝŶŝƚŝĂůůŽŐŝĐŵŽĚĞů
ƚŽĚĞĨŝŶĞĞǀŝĚĞŶĐĞŶĞĞĚƐ ?ŽĨƚŚĞ/Ed'ZATE-HTA Model (9). The economic modelling guidance 
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expands on the HTA logic modelling by developing descriptions of the health systems that enable the 
potential impact of the intervention on economically relevant, resource, cost and effectiveness 
outcomes to be made explicit. The systems approach enables the economic conceptual modelling to 
be made coherent with the other HTA dimensions, including effectiveness, ethical, socio-cultural and 
context, and legal elements (4). The guidance recommends including a formal consideration of 
aspects of complexity in developing an understanding of the decision problem and scope for 
economic evaluation and updating this during the project. This should include in-depth exploration of 
the economic implications of those aspects of complexity described in the introduction, including 
indeterminate phenomena (for example understanding of variation in the intervention, its 
implementation, and in the system into which it will be introduced), uncertain causality (e.g. factors 
that influence how the intervention impacts on the system and economic outcomes) and historicity, 
that is the time, place and system context of an intervention. 
The guidance also recommends an increased role for multi-agency cost consequence analysis (CCA) 
to support decision making in the presence of multiple perspectives. The use of formal consideration 
of complexity aspects to ensure that stakeholders have a comprehensive understanding of the 
evidence base and the economic model, and specifically their limits of applicability to ensure 
appropriate interpretation of quantitative economic outcomes in decision making.  
Recommendations for research include methodological development on the role of computational 
complexity science methods to support health economics within HTA, the use of computational 
modelling techniques, such as agent based modelling and social network analysis for understanding 
the health economic impact of adaptive behaviour and co-evolutions of intervention and setting 
within HTA and the modelling of behaviour within health economic models. Methods for measuring, 
valuing and incorporating non Whealth benefits into the HTA process require development. 
 
Guidance for the assessment of ethical aspects 
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In the same manner as with the guidance for assessing effectiveness and economic aspects in HTA 
the guidance on ethical aspects is developed to address methodological challenges posed by the 
complexity of the intervention. The point of departure for the ethics guidance is the fact that a 
number of ethical approaches are available for use in HTA, e.g. Principlism, Casuistry, Wide Reflective 
Equilibrium, Social Shaping of Technology, Interactive technology assessment, The triangular model, 
The HTA Core Model, and The Socratic approach. These approaches may be more or less suitable, 
depending on the complexity of the technology and the context. For instance, the ability to detect 
ethical issues embedded in the many/various/unpredictable outcomes may vary between the 
approaches. This calls for a methodical flexibility, which may be demanding for the assessor. Hence, 
the guidance presents a procedural framework to assists in how to select, modify/expand, and use 
the various existing ethical approaches. 
 
To deal with ethical issues in a structured way the guidance suggests a stepwise application. The first 
two steps address the selection of the most appropriate ethical approach. This starts with assessing 
the complexity of the technology against a set of ethically relevant complexity characteristics, i.e. 
ĚĞƚĞƌŵŝŶŝŶŐƚŚĞƚĞĐŚŶŽůŽŐǇ ?Ɛ ‘ĐŽŵƉůĞǆŝƚǇƉƌŽĨŝůĞ ? ?ƐƚĞƉ ? ? ?ĨŽůůŽǁĞĚďǇĂƐƐĞƐƐŝŶŐŚŽǁƚŚĞǀĂƌŝŽƵƐ
ethical approaches fit this complexity profile in general (step 2). The choice of ethical approach also 
includes assessing the ethical approaches against some relevant local HTA characteristics (i.e. the 
integration perspective, and the aim for assessment vs. appraisal). Despite a systematic and 
thorough selection process, the standard ethical approach may not fit perfectly for the HTA in 
question. For example, the best available approach may not address all important ethical issues of 
the technology at hand. Accordingly, it may be necessary to modify the approach, which is carried 
out in step 3. As detailed descriptions of how to apply the different ethical approaches are available 
in the literature, the approaches are only introduced in the guidance and references to further 
reading is provided to assist (non-ethicists) in the application process (step 4). Further, the need for 
bilateral integration across HTA aspect in the application process is highlighted. The outcomes of the 
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ethical assessment (step 5) are not constrained to specific ethical areas (e.g. concerning the patient 
group, the health technology, the implementation or the HTA process), as the outcomes depends on 
the chosen approach and how it is applied for the health technology at hand. 
 
When following the steps of the guidance the users are provided with tools facilitating the choice 
and adjustments of the ethical approaches, such as illustrating the meaning and implications of the 
five complexity characteristics, providing the overview of available ethical approaches, and listing 
some of relevant features of each approach. Moreover, the guidance indicates the value of 
stakeholder involvement in the different steps, e.g. as a source of information when determining the 
complexity profile of the health technology (step 1) and in validating the outcome of the ethical 
assessment (step 5). Overall, the guidance increases the awareness of challenges and opportunities 
embedded in the ethical approaches and of applying them in a local context, i.e. as other parts of the 
guidance, the ethics part is dynamic and adaptive to the complexity of the technology and the 
context rather than offering a one-size-fits-all approach. 
Guidance for the assessment of socio-cultural aspects 
This part of the guidance provides a structured approach to include the assessment of socio-cultural 
ĂƐƉĞĐƚƐŝŶ,d ?ĂŶĚƚŽŝŶĐƌĞĂƐĞƚŚĞƵƐĞƌ ?ƐƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨƚŚĞĂƐƐĞƐƐŵĞŶƚŽĨƐŽĐŝŽ-cultural aspects 
of health technologies, methodological challenges and solutions involved. Socio-cultural aspects are 
of special interest in complex interventions due to potential interactions between the technology 
and the socio-cultural context in which the technology would be used. 
The guidance on socio-cultural aspects offers new methodological tools and procedures for the 
assessment of socio-cultural aspects. It provides an inductively developed framework and a stepwise 
assessment process as well as an option to identify and address cultural heterogeneity of different 
social groups. The assessment process contains five-steps: 1) The assessment of the complexity of a 
technology, 2) The identification and prioritization of relevant socio-cultural aspects and 
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stakeholders, 3) The validation of identified aspects, 4) The assessment of the prioritized aspects, and 
5) The presentation of the evidence. 
The socio-cultural framework is a comprehensive tool to identify and evaluate socio-cultural aspects 
on different levels of social organization and from the perspectives of social and cultural groups. It 
can be applied on each of the five steps in the assessment process. For example in step 1) to identify 
relevant complexity issues from a socio-cultural perspective, based on the list of complexity 
characteristics provided in the ethics part of the guidance. The framework consists of main 
categories and subcategories and outline aspects of interest for the socio-cultural assessment within 
these categories. The first catĞŐŽƌǇŝƐ ‘ƚŚĞƐŽĐŝĂůƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨƚŚĞŚĞĂůƚŚŝƐƐƵĞ ?ĂŶĚƚŚĞƐĞĐŽŶĚŝƐ
 ‘ƚŚĞƐŽĐŝĂůƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨƚŚĞƚĞĐŚŶŽůŽŐǇ ? ?dŚĞůĂƚƚĞƌĐŽǀĞƌƐ ‘ƚŚĞƉĞƌĐĞŝǀĞĚƵƐĞĨƵůŶĞƐƐ ? ? ‘ƚŚĞ
ŬŶŽǁůĞĚŐĞĂŶĚƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨƚŚĞƚĞĐŚŶŽůŽŐǇ ? ? ‘ĂƚƚŝƚƵĚĞƐƚŽĂŶĚƚŚĞĂĐĐĞƉƚĂŶĐĞŽĨƚhe 
ƚĞĐŚŶŽůŽŐǇ ? ?ĂŶĚ ‘ƚŚĞƌŝƐŬƉĞƌĐĞƉƚŝŽŶĂŶĚŚĂŶĚůŝŶŐ ? ?dŚĞůĂƐƚŵĂŝŶĐĂƚĞŐŽƌǇŝƐ ‘ƚŚĞƐŽĐŝŽ-cultural 
ĂƐƉĞĐƚƐŽĨƚŚĞƚĞĐŚŶŽůŽŐǇ ?ƐŝŵƉůĞŵĞŶƚĂƚŝŽŶ ? ?ǁŚŝĐŚĐŽǀĞƌƐ ‘ƐŽĐŝŽ-cultural aspects of the target 
ŐƌŽƵƉƐ ? ? ‘ƐŽĐŝĂůŝŶĞƋƵĂůŝƚǇ ? ? ‘ƚŚĞƵƐĞƌ-professional-relatŝŽŶƐŚŝƉ ?ĂŶĚ ‘ƌĞůĂƚŝŽŶƐŚŝƉƐďĞƚǁĞĞŶ
ƉƌŽĨĞƐƐŝŽŶĂůƐƉƌŽǀŝĚŝŶŐƚŚĞƚĞĐŚŶŽůŽŐǇ ? ?
tŚĞŶĂƉƉůǇŝŶŐƚŚŝƐĨƌĂŵĞǁŽƌŬƚŚĞƵƐĞƌǁŝůůĨŝŶĚƐƵƉƉŽƌƚŝŶƚĞƌŵƐŽĨƚŚŽƌŽƵŐŚĚĞƐĐƌŝƉƚŝŽŶŽĨ ‘ƚŚĞ
ĂƐƉĞĐƚƐŽĨŝŶƚĞƌĞƐƚ ?ĂŶĚůŝƐƚs of related assessment questions (e.g., «How do different professional 
ĐƵůƚƵƌĞƐŝŶĨůƵĞŶĐĞƚŚĞƉƌŽǀŝƐŝŽŶŽĨƚŚĞƚĞĐŚŶŽůŽŐǇ ? ?  “ŽĚŝĨĨĞƌĞŶƚŐƌŽƵƉƐƉĞƌĐĞŝǀĞƌŝƐŬƐƌĞůĂƚĞĚƚŽ
ƚŚĞƚĞĐŚŶŽůŽŐǇĚŝĨĨĞƌĞŶƚůǇ ? ? ? “tŚǇĚŽĞƐƚŚĞƚĞĐŚŶŽůŽŐǇǁŽƌŬ ?ŝƐĂĐĐĞƉƚĞĚŝŶŽŶĞĐƵůƚƵƌĂůĐŽŶƚĞǆƚĂŶĚ
ŶŽƚŝŶĂŶŽƚŚĞƌ ? ? ? “ŽĞƐƚŚĞŝŵƉůĞŵĞŶƚĂƚŝŽŶ ?ƵƐĞŽĨĂƚĞĐŚŶŽůŽŐǇůĞĂĚƚŽƐŽĐŝĂůŝŶĞƋƵĂůŝƚŝĞƐ ? ? ? ?ǁŚŝĐŚ
facilitates a systematic assessment of the different aspects. Additionally, illustrating examples from 
application in home based palliative care are provided. 
Application of the guidance facilitates the explicit identification and evaluation of socio-cultural 
aspects and thereby generates a broader understanding of these aspects from different perspectives 
as well as at different levels (micro-, meso-, and macro-level) of the social organisation. It also takes 
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into account linkages to context and implementation and offers an option to include and 
systematically address cultural heterogeneity of perspectives within the HTA process.  
 
Guidance for the assessment of legal aspects 
Legal aspects of health technologies are diverse and difficult to assess within a generic framework. 
This problem is exacerbated for complex technologies and interventions where the range of 
potentially relevant legal aspects is more diverse. An example might be a drug-supported 
psychological intervention in which for some parts of the intervention the legal issue of market 
authorisation is most crucial (the pharmaceutical product) while others rather have implications for 
privacy and data protection (the psychological interventions). Furthermore, the importance of 
different legal aspects is dependent on the addressee and user of the HTA (i.e. the level of the 
decision that shall be based on the HTA-report). The legal aspect of informed consent might not be 
important for the hospital management users of an HTA-report when deciding to buy a new medical 
device, but used as a guideline for the clinical staff the HTA-report must point out that informed 
consent of the patient to be treated with the same device is an absolute condition. Assessing legal 
aspects in HTA is therefore heavily dependent on the identification of the most important legal 
implications, depending of the respective technology assessed as well as the relevant decision level 
on which the HTA-report is to be used.  
 
The INTEGRATE-HTA guidance for legal aspects in HTA aims at supporting HTA researchers in 
identifying the respective relevant legal fields and the potential need for further legal inquiry. The 
guidance focuses on nine legal core issues, which have been identified as mostly crucial for the 
assessment of different technologies and are related to different decision levels. Three of these core 
issues, the informed consent, alternative forms of consent and privacy and data protection can be 
ƐƵďƐƵŵĞĚƵŶĚĞƌƚŚĞƚĞƌŵ ‘ƵƚŽŶŽŵǇŽĨƚŚĞWĂƚŝĞŶƚ ? ?ƚǁŽĐŽŶĐĞƌŶƚŚĞůĞŐĂůĨŝĞůĚŽĨŵĂƌŬĞƚ
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authorisation, specifically of medical devices and medicinal products. The other four legal issues are 
clinical trials, intellectual properties, reimbursement in public health care systems and special 
medical fields. For each of these issues the guidance provides a brief introduction followed by: 1) an 
initial question, 2) a short explanation of the legal issue, often including examples, 3) an overview 
over relevant legal sources, 4) relations of the legal aspect to other parts of the HTA and finally 5) a 
reference on the decision level on which the aspect is relevant. 
 
The guidance is applied by answering the initial question, using the further explanations to assess 
whether or not the legal aspect is of relevance for the respective technology. If the aspect is of 
importance, the further steps can be used to assess the need for and to start an in-depth analysis of 
the aspect within the HTA. It is important to note that this generic guidance does not seek to 
substitute for case based legal advice, in assessments where the legal aspect is considered to be of 
paramount importance and potentially unclear, a professional legal advisor should always be 
consulted. In this way the legal guidance provides a decent framework, not for a conclusive 
clarification of all possibly affected legal aspects of a technology but for identifying such aspects and 
for identifying when further measures are advisable or necessary. 
 
Discussion 
The brief presentation of the five aspects included in the Guidance for assessing effectiveness, 
economic aspects, ethical aspects, socio-cultural aspects and legal aspects in complex technologies, 
(4) reveals similarities but also some differences between them. Differences stem from disparities in 
the perspective, traditions and state of methodological development of the five disciplines. For 
instance whilst there is a wealth of methodologies for assessing effectiveness, economic and ethical 
aspects, there is substantially less methodological guidance available for the assessment of socio-
cultural and legal aspects. Hence, the latter two focus on developing new methods, while the former 
three focuses more on complementing and expanding on existing methods.  
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 As the various parts of guidance are developed in the same vein, all parts of the guidance offers 
systematic, stepwise approaches, which also includes involving stakeholders and their perspectives 
systematically. Such a systematic assessment process is highly welcome in the "unclear terrain" of 
assessing complex health technologies. Additionally, all guidance parts emphasize the possible need 
for flexibility in choosing and applying methods when dealing with complex interventions. This 
flexibility reflects that the presence of complexity have stronger implications for the planning, con-
duct and interpretation of the HTA (which is the focus of the guidance) for some health technologies 
than for others. Hence, an understanding of the impact of technologies complexity is always useful, 
in order to make appropriate methodological choices. A further common feature is that all parts of 
the guidance provide examples of how they can be applied, mostly drawing on the case study of 
home based palliative care (11). The value of providing examples may be particularly high when 
dealing with the challenges of complexity.  
Throughout the guidance we have indicated the interrelations between the five assessment aspects 
and the possibilities for integration. For instance, the economic analysis may point out a need for 
addressing the ethical question about fair distribution of resources, which may relate to legal 
regulation of priority setting. Furthermore, we have explained how and where this guidance fits into 
The INTEGRATE-HTA Model (9). This does not exclude the users possibility to apply one/some parts 
of the guidance separately (e.g. to assess only the legal issues of the technology). However, it is 
strongly recommended to address the different parts in a comprehensive and integrated HTA.  
Nonetheless, the issue of integration across assessment aspects seems to be persistent in HTA (19), 
and we recognize that the methods for integration across assessment aspects need further 
development. Overlaps between assessment aspects are particularly relevant for ethical and socio-
cultural aspects, explaining why they can be addressed together (e.g. in a common literature search) 
(20). The inherent links between the economics and the effectiveness assessment means that a close 
sharing of identified primary evidence, of extracted results, and of synthesized evidence is beneficial 
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in assessing both assessment aspects. Moreover, in the application of the guidance in the case study 
of home based palliative care, we found a number of concepts and issues (e.g. access and availability) 
relevant across all assessment aspects, and that the perspective of one aspect can have impact on 
the assessment of other aspects.  
 
Conclusion 
The Guidance for assessing effectiveness, economic aspects, ethical aspects, socio-cultural aspects 
and legal aspects in complex technologies (6) adds value to HTA by providing a practical step by step 
guidance on assessing complex health technologies. While it has been recognised that all 
technologies are to some degree complex, the key issue is to understand when the complexity 
matters for HTA and for decision makers, and specifically when special methods need to be 
employed in the assessment of a technology. By putting forward systematic approaches to describe 
aspects of complexity this guidance seeks to enable appropriate methodological choices to be made. 
It brings together assessments from distinct disciplines, such as epidemiology, economics, ethics, 
law, and social theory. As this integration is not necessarily specific to the level of complexity of an 
intervention or system, the guidance can have a much broader potential relevance. 
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